No automatic approval of post-market changes to biologics in India
This article was originally published in SRA
The Indian drug regulatory agency, the Central Drugs Standard Control Organization, has done away with a provision that allowed manufacturers of biological drugs to obtain default clearance of post-approval changes to their products if the agency did not respond to valid applications within a specific time period1,2.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.